Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A1 | Q14973 | 15/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21427896 | 1.00 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2TSHRMAPT | |
| SCHEMBL30361236 | 1.00 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2TSHRMAPT | |
| SCHEMBL21408544 | 1.00 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2TSHRMAPT | |
| SCHEMBL21408543 | 1.00 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2TSHRMAPT | |
| SCHEMBL21408355 | 0.94 | SLC10A1 (0.47) | SLC10A1GRM4LRRK2 | |
| SCHEMBL30361242 | 0.94 | SLC10A1 (0.47) | SLC10A1GRM4LRRK2 | |
| SCHEMBL21408396 | 0.93 | SLC10A1 (0.46) | SLC10A1GRM4LRRK2ALDH1A1 | |
| SCHEMBL21428046 | 0.93 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 | |
| SCHEMBL21408395 | 0.93 | SLC10A1 (0.46) | SLC10A1GRM4LRRK2ALDH1A1 | |
| SCHEMBL30361258 | 0.93 | SLC10A1 (0.49) | SLC10A1GRM4LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228818-A1 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228818-A1 | PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR | TPMT, PNP, GTF3C3 | SLC10A1 14/4885GRM4 4636/4885LRRK2 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.